2017 Form 10-K Financial Statement
#000143774918006937 Filed on April 16, 2018
Income Statement
| Concept | 2017 | 2016 Q4 | 2016 Q2 |
|---|---|---|---|
| Revenue | $721.0K | $160.0K | $134.9K |
| YoY Change | -67.29% | -90.06% | -95.34% |
| Cost Of Revenue | $1.091M | $280.0K | $175.8K |
| YoY Change | -32.35% | -75.86% | -92.62% |
| Gross Profit | -$370.0K | -$110.0K | -$40.96K |
| YoY Change | -162.5% | -124.44% | -107.98% |
| Gross Profit Margin | -51.31% | -68.75% | -30.37% |
| Selling, General & Admin | $4.537M | $1.910M | $840.1K |
| YoY Change | -38.08% | -29.0% | -80.7% |
| % of Gross Profit | |||
| Research & Development | $1.328M | $470.0K | $224.4K |
| YoY Change | -15.42% | -32.86% | -62.47% |
| % of Gross Profit | |||
| Depreciation & Amortization | $1.114M | $320.0K | $209.0K |
| YoY Change | -1.04% | 52.38% | 16.11% |
| % of Gross Profit | |||
| Operating Expenses | $15.16M | $2.380M | $1.065M |
| YoY Change | 70.44% | -29.79% | -78.5% |
| Operating Profit | -$15.53M | -$2.490M | -$1.105M |
| YoY Change | 87.05% | -15.31% | -75.09% |
| Interest Expense | -$10.82K | $0.00 | -$109.00 |
| YoY Change | -95.76% | -100.0% | -99.99% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $555.5K | $10.00K | -$189.4K |
| YoY Change | 506.44% | -100.03% | -105.3% |
| Pretax Income | -$14.98M | -$2.480M | -$1.295M |
| YoY Change | -166.64% | -94.14% | 49.63% |
| Income Tax | $0.00 | $0.00 | |
| % Of Pretax Income | |||
| Net Earnings | -$14.98M | -$2.480M | -$1.295M |
| YoY Change | -166.64% | -94.13% | 48.79% |
| Net Earnings / Revenue | -2077.36% | -1550.0% | -960.16% |
| Basic Earnings Per Share | -$1.02 | $0.17 | |
| Diluted Earnings Per Share | -$1.02 | -$0.24 | -$0.13 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 14.65M | 9.927M shares | 9.794M |
| Diluted Shares Outstanding | 14.65M | 9.794M |
Balance Sheet
| Concept | 2017 | 2016 Q4 | 2016 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $693.5K | $2.620M | $6.070M |
| YoY Change | -73.53% | 184.78% | -11.9% |
| Cash & Equivalents | $2.620M | $10.36M | |
| Short-Term Investments | |||
| Other Short-Term Assets | $341.7K | $380.0K | $750.0K |
| YoY Change | -11.93% | -55.29% | -75.33% |
| Inventory | $35.59K | $69.95K | $56.35K |
| Prepaid Expenses | |||
| Receivables | $114.3K | $290.0K | $1.230M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $1.185M | $3.372M | $12.35M |
| YoY Change | -64.86% | 10.6% | -3.69% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $223.6K | $486.1K | $865.7K |
| YoY Change | -54.0% | -56.41% | -0.95% |
| Goodwill | $2.079M | $2.100M | |
| YoY Change | 86.08% | ||
| Intangibles | $7.840M | $8.400M | |
| YoY Change | 211.95% | -70.62% | |
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $15.32K | $278.7K | $340.0K |
| YoY Change | -94.5% | -29.66% | -88.83% |
| Total Long-Term Assets | $238.9K | $10.68M | $11.70M |
| YoY Change | -97.76% | 165.46% | -65.23% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $1.185M | $3.372M | $12.35M |
| Total Long-Term Assets | $238.9K | $10.68M | $11.70M |
| Total Assets | $1.424M | $14.06M | $24.05M |
| YoY Change | -89.87% | 98.72% | -48.24% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $380.3K | $392.6K | $2.877M |
| YoY Change | -3.14% | -63.2% | 65.53% |
| Accrued Expenses | $556.6K | $1.055M | $3.112M |
| YoY Change | -47.23% | -57.01% | -45.6% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | $0.00 | |
| YoY Change | -100.0% | ||
| Total Short-Term Liabilities | $936.8K | $1.447M | $5.989M |
| YoY Change | -35.27% | -96.57% | -23.81% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Other Long-Term Liabilities | $4.330K | $123.4K | $171.6K |
| YoY Change | -96.49% | -59.8% | -65.49% |
| Total Long-Term Liabilities | $4.330K | $123.4K | $171.6K |
| YoY Change | -96.49% | -86.93% | -65.49% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $936.8K | $1.447M | $5.989M |
| Total Long-Term Liabilities | $4.330K | $123.4K | $171.6K |
| Total Liabilities | $941.2K | $1.571M | $2.789M |
| YoY Change | -40.08% | -96.36% | -89.57% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$5.696M | $0.00 | |
| YoY Change | -96.5% | -100.0% | |
| Common Stock | $993.00 | $993.00 | |
| YoY Change | -92.04% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $482.9K | $12.49M | $17.89M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $1.424M | $14.06M | $24.05M |
| YoY Change | -89.87% | 98.72% | -48.24% |
Cashflow Statement
| Concept | 2017 | 2016 Q4 | 2016 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$14.98M | -$2.480M | -$1.295M |
| YoY Change | -166.64% | -94.13% | 48.79% |
| Depreciation, Depletion And Amortization | $1.114M | $320.0K | $209.0K |
| YoY Change | -1.04% | 52.38% | 16.11% |
| Cash From Operating Activities | -$4.904M | -$1.360M | -$4.830M |
| YoY Change | -55.12% | -50.36% | -2.62% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | ||
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $1.910K | $100.0K | $0.00 |
| YoY Change | -98.09% | 150.0% | -100.0% |
| Cash From Investing Activities | $1.914K | $100.0K | $0.00 |
| YoY Change | -98.09% | -125.64% | -100.0% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | -$2.922M | ||
| YoY Change | -141.43% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 2.922M | 0.000 | 10.20M |
| YoY Change | -76.67% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -4.904M | -1.360M | -4.830M |
| Cash From Investing Activities | 1.914K | 100.0K | 0.000 |
| Cash From Financing Activities | 2.922M | 0.000 | 10.20M |
| Net Change In Cash | -1.980M | -1.260M | 5.370M |
| YoY Change | -216.63% | -59.74% | -208.92% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$4.904M | -$1.360M | -$4.830M |
| Capital Expenditures | $0.00 | ||
| Free Cash Flow | -$4.830M | ||
| YoY Change | -2.62% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q4 | aurx |
Accrued Loss On Abandonment Of Lease
AccruedLossOnAbandonmentOfLease
|
88560 | |
| CY2016Q4 | aurx |
Accrued Loss On Abandonment Of Lease
AccruedLossOnAbandonmentOfLease
|
88560 | |
| CY2014Q4 | aurx |
Accrued Machine Refurbishment And Design Improvement Costs
AccruedMachineRefurbishmentAndDesignImprovementCosts
|
600000 | |
| CY2017Q4 | aurx |
Accrued Machine Refurbishment And Design Improvement Costs
AccruedMachineRefurbishmentAndDesignImprovementCosts
|
||
| CY2016Q4 | aurx |
Accrued Machine Refurbishment And Design Improvement Costs
AccruedMachineRefurbishmentAndDesignImprovementCosts
|
465000 | |
| CY2017Q4 | aurx |
Authorized Shares Common And Preferred
AuthorizedSharesCommonAndPreferred
|
32500000 | |
| CY2017 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2017 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | |
| CY2017 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-12-31 | |
| CY2017 | dei |
Document Type
DocumentType
|
10-K | |
| CY2017Q2 | dei |
Entity Public Float
EntityPublicFloat
|
2200000 | |
| CY2016Q2 | aurx |
Fresh Start Accounting Percent Of Voting Share Of Emerging Entity
FreshStartAccountingPercentOfVotingShareOfEmergingEntity
|
0.5 | |
| CY2017 | aurx |
Noncash Gain Loss On Reorganisation
NoncashGainLossOnReorganisation
|
||
| aurx |
Noncash Gain Loss On Reorganisation
NoncashGainLossOnReorganisation
|
|||
| CY2016Q2 | aurx |
Payment For Offering Cost
PaymentForOfferingCost
|
100000 | |
| aurx |
Payments For Reorganization Items
PaymentsForReorganizationItems
|
1507863 | ||
| CY2017 | aurx |
Percentage Of Revenues Generated Outside Of United States
PercentageOfRevenuesGeneratedOutsideOfUnitedStates
|
0.27 | |
| CY2016Q2 | aurx |
Fresh Start Adjustment Increase Decrease Common And Preferred Stock At Par
FreshStartAdjustmentIncreaseDecreaseCommonAndPreferredStockAtPar
|
-753 | |
| aurx |
Percentage Of Revenues Generated Outside Of United States
PercentageOfRevenuesGeneratedOutsideOfUnitedStates
|
0.22 | ||
| aurx |
Percentage Of Revenues Generated Outside Of United States
PercentageOfRevenuesGeneratedOutsideOfUnitedStates
|
0.11 | ||
| CY2016Q2 | aurx |
Post Confirmation Tangible Assets
PostConfirmationTangibleAssets
|
13574000 | |
| CY2016Q2 | aurx |
Post Confirmation Tangible Assets
PostConfirmationTangibleAssets
|
13574000 | |
| CY2016Q2 | aurx |
Postconfirmation Accrued Interest Current
PostconfirmationAccruedInterestCurrent
|
||
| CY2016Q2 | aurx |
Postconfirmation Common Stock Issuable
PostconfirmationCommonStockIssuable
|
||
| CY2016Q2 | aurx |
Postconfirmation Conditionally Redeemable Common Stock
PostconfirmationConditionallyRedeemableCommonStock
|
||
| CY2016Q2 | aurx |
Postconfirmation Convertible Debt Subject To Put Rights
PostconfirmationConvertibleDebtSubjectToPutRights
|
||
| CY2016Q2 | aurx |
Postconfirmation Deferred Costs And Other Assets Noncurrent
PostconfirmationDeferredCostsAndOtherAssetsNoncurrent
|
355741 | |
| CY2016Q2 | aurx |
Preconfirmation Accrued Interest Current
PreconfirmationAccruedInterestCurrent
|
3316121 | |
| CY2016Q2 | aurx |
Preconfirmation Common Stock Issuable
PreconfirmationCommonStockIssuable
|
392950 | |
| CY2016Q2 | aurx |
Preconfirmation Conditionally Redeemable Common Stock
PreconfirmationConditionallyRedeemableCommonStock
|
500000 | |
| CY2016Q2 | aurx |
Preconfirmation Convertible Debt Subject To Put Rights
PreconfirmationConvertibleDebtSubjectToPutRights
|
35000000 | |
| CY2016Q2 | aurx |
Preconfirmation Deferred Costs And Other Assets Noncurrent
PreconfirmationDeferredCostsAndOtherAssetsNoncurrent
|
355741 | |
| CY2016Q2 | aurx |
Debt Free Net Cash Flow Growth Rate
DebtFreeNetCashFlowGrowthRate
|
0.034 | |
| CY2016Q4 | aurx |
Debt Instrument Number Of Periodic Payments
DebtInstrumentNumberOfPeriodicPayments
|
3 | |
| CY2017 | aurx |
Debt Issuance Costs On Short Term Debtor In Posession Note Payable
DebtIssuanceCostsOnShortTermDebtorInPosessionNotePayable
|
||
| aurx |
Debt Issuance Costs On Short Term Debtor In Posession Note Payable
DebtIssuanceCostsOnShortTermDebtorInPosessionNotePayable
|
|||
| aurx |
Debtor Reorganization Items Gain Loss On Reorganization Adjustments Net
DebtorReorganizationItemsGainLossOnReorganizationAdjustmentsNet
|
|||
| CY2017Q4 | aurx |
Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
|
372425 | |
| CY2016Q4 | aurx |
Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
|
||
| CY2017Q4 | aurx |
Deferred Tax Assets Liabilities Excluding Operating Loss Carryforward
DeferredTaxAssetsLiabilitiesExcludingOperatingLossCarryforward
|
4429969 | |
| CY2016Q4 | aurx |
Deferred Tax Assets Liabilities Excluding Operating Loss Carryforward
DeferredTaxAssetsLiabilitiesExcludingOperatingLossCarryforward
|
2153376 | |
| CY2017Q4 | aurx |
Deferred Tax Assets Start Up And Organizational Costs
DeferredTaxAssetsStartUpAndOrganizationalCosts
|
165603 | |
| CY2016Q4 | aurx |
Deferred Tax Assets Start Up And Organizational Costs
DeferredTaxAssetsStartUpAndOrganizationalCosts
|
270652 | |
| CY2017 | aurx |
Direct Operating Cost Royalty Expense Recovery
DirectOperatingCostRoyaltyExpenseRecovery
|
||
| aurx |
Direct Operating Cost Royalty Expense Recovery
DirectOperatingCostRoyaltyExpenseRecovery
|
|||
| CY2016Q2 | aurx |
Freshstart Adjustment Increase Decrease Common Stock Issuable
FreshstartAdjustmentIncreaseDecreaseCommonStockIssuable
|
-392950 | |
| CY2016Q2 | aurx |
Freshstart Adjustment Increase Decrease Intangible Assets Including Goodwill
FreshstartAdjustmentIncreaseDecreaseIntangibleAssetsIncludingGoodwill
|
10476284 | |
| CY2017Q2 | aurx |
Goodwill Carrying Amount Exceeding Fair Value
GoodwillCarryingAmountExceedingFairValue
|
2800000 | |
| CY2017 | aurx |
Preferred Stock Issued
PreferredStockIssued
|
||
| aurx |
Preferred Stock Issued
PreferredStockIssued
|
8288719 | ||
| CY2016Q2 | aurx |
Preferred Stock Issued During Period Value New Issues
PreferredStockIssuedDuringPeriodValueNewIssues
|
8288719 | |
| CY2017 | aurx |
Proceeds From Issuance Of Commonstock And Preferred Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonstockAndPreferredStockNetOfIssuanceCosts
|
2922500 | |
| aurx |
Proceeds From Issuance Of Commonstock And Preferred Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonstockAndPreferredStockNetOfIssuanceCosts
|
|||
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Accrued Interest
ReorganizationAdjustmentIncreaseDecreaseAccruedInterest
|
-3316121 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Additional Paidin Capital
ReorganizationAdjustmentIncreaseDecreaseAdditionalPaidinCapital
|
-126011808 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Assets
ReorganizationAdjustmentIncreaseDecreaseAssets
|
-2422510 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Common Stock
ReorganizationAdjustmentIncreaseDecreaseCommonStock
|
-12477 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Conditionally Redeemable Common Stock
ReorganizationAdjustmentIncreaseDecreaseConditionallyRedeemableCommonStock
|
-500000 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Convertible Debt Subject To Put Rights
ReorganizationAdjustmentIncreaseDecreaseConvertibleDebtSubjectToPutRights
|
-35000000 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Current Assets
ReorganizationAdjustmentIncreaseDecreaseCurrentAssets
|
-16053 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Deferred Revenue Current Portion
ReorganizationAdjustmentIncreaseDecreaseDeferredRevenueCurrentPortion
|
-899920 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Elimination Of Various Payables And Accruals
ReorganizationAdjustmentIncreaseDecreaseEliminationOfVariousPayablesAndAccruals
|
-773756 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Equity Excluding Retained Earnings
ReorganizationAdjustmentIncreaseDecreaseEquityExcludingRetainedEarnings
|
-126917235 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Intangible Assets Net Excluding Goodwill
ReorganizationAdjustmentIncreaseDecreaseIntangibleAssetsNetExcludingGoodwill
|
-2406457 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Liabilities
ReorganizationAdjustmentIncreaseDecreaseLiabilities
|
-45739797 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Liabilities And Stockholders Equity
ReorganizationAdjustmentIncreaseDecreaseLiabilitiesAndStockholdersEquity
|
-2422510 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Liabilities Subject To Compromise
ReorganizationAdjustmentIncreaseDecreaseLiabilitiesSubjectToCompromise
|
-39089877 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Prepaid And Other Current Assets
ReorganizationAdjustmentIncreaseDecreasePrepaidAndOtherCurrentAssets
|
-16053 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Retained Earnings Deficit
ReorganizationAdjustmentIncreaseDecreaseRetainedEarningsDeficit
|
170234522 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Stockholders Equity
ReorganizationAdjustmentIncreaseDecreaseStockholdersEquity
|
43817287 | |
| CY2016Q2 | aurx |
Reorganization Adjustment Increase Decrease Termination Of Debt Agreements And Accrued Interest
ReorganizationAdjustmentIncreaseDecreaseTerminationOfDebtAgreementsAndAccruedInterest
|
-44066121 | |
| CY2016Q2 | aurx |
Warrant Expiration Date
WarrantExpirationDate
|
2021-05-05 | |
| CY2017Q4 | us-gaap |
Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
|
114331 | |
| CY2016Q4 | us-gaap |
Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
|
294298 | |
| CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
380280 | |
| CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
392615 | |
| CY2017Q4 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
420226 | |
| CY2016Q4 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
703675 | |
| CY2017Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
80764 | |
| CY2016Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
91325 | |
| CY2017Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
556557 | |
| CY2016Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1054677 | |
| CY2017Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
124852 | |
| CY2016Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
213116 | |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
538724 | |
| CY2016Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
279601 | |
| CY2017Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
21155404 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
18180658 | |
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
74999 | ||
| CY2017 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
53526 | |
| CY2017Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
306000 | |
| CY2016Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
409000 | |
| CY2017Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
305895 | |
| CY2016Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
409377 | |
| CY2017 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
852000 | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
600000 | ||
| CY2017Q4 | us-gaap |
Assets
Assets
|
1424039 | |
| CY2016Q4 | us-gaap |
Assets
Assets
|
14056753 | |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
1185107 | |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
3372215 | |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
693515 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2620023 | |
| CY2016Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
10358209 | |
| CY2017 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-1926508 | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-7738186 | ||
| CY2017Q4 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
250000 | |
| CY2017Q4 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
400000 | |
| CY2016Q2 | us-gaap |
Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
|
2016-11-05 | |
| CY2017Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2016Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
31500000 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
31500000 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22722400 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
9927112 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22722400 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
9927112 | |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2272 | |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
993 | |
| CY2017 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Credit Concentration</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">We generate accounts receivable from the sale of our products. Specific customer receivables balances in excess of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of total receivables at <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2016 </div>were as follows:</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-right: 20%; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 62%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer A</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">58</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer B</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer C</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">%</div> </td> </tr> </table> </div> <div style=" margin: 0pt 7.5pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Revenue from significant customers exceeding <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of total revenues for the periods presented was as follows:</div> <div style=" margin: 0pt 7.5pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-right: 10%; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Period from</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">May 5, 2016</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">through</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Period from</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">January 1, 2016</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">through May 4,</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Successor</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Successor</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Predecessor</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 49%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer B</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">78</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer C</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer D</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 36pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </table> </div> <div style=" margin: 0pt 7.5pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 7.5pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Historically, we used single suppliers for several components of the Aurix™ product line. We outsource the manufacturing of various products to contract manufacturers. While we believe these manufacturers demonstrate competency, reliability and stability, there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more of them will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experience an interruption or inability to provide us with the products needed to satisfy customer demand. Additionally, while most of the components of Aurix™ are generally readily available on the open market, a reagent, bovine thrombin, is available exclusively through Pfizer, with whom we have an established vendor relationship.</div></div></div> | |
| CY2017 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
1091042 | |
| us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
729050 | ||
| CY2017 | us-gaap |
Cost Of Goods Sold Amortization
CostOfGoodsSoldAmortization
|
731000 | |
| CY2017 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
1091042 | |
| us-gaap |
Cost Of Revenue
CostOfRevenue
|
729050 | ||
| CY2017 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
0 | |
| CY2017 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
0 | |
| CY2017Q4 | us-gaap |
Customer Deposits Current
CustomerDepositsCurrent
|
20896 | |
| CY2016Q4 | us-gaap |
Customer Deposits Current
CustomerDepositsCurrent
|
72192 | |
| CY2016Q4 | us-gaap |
Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
|
33333 | |
| CY2017Q4 | us-gaap |
Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
|
0 | |
| CY2016Q4 | us-gaap |
Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
|
0 | |
| us-gaap |
Debtor Reorganization Items Legal And Advisory Professional Fees
DebtorReorganizationItemsLegalAndAdvisoryProfessionalFees
|
324551 | ||
| CY2017 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-14164539 | |
| CY2017Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
||
| CY2016Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
2374950 | |
| CY2017 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
576990 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
190777 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
354831 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
4429969 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
4528326 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Gross Noncurrent
DeferredTaxAssetsGrossNoncurrent
|
39279354 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Gross Noncurrent
DeferredTaxAssetsGrossNoncurrent
|
52866903 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
34849385 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
50713527 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
117537 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
224910 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
68644 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
163755 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
|
30808 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
|
29379 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
39279354 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
52866903 | |
| CY2017Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
||
| CY2016Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
||
| CY2017Q4 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
|
||
| CY2016Q4 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
|
2374950 | |
| CY2017 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
262000 | |
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
249000 | ||
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
280000 | ||
| CY2017 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1113857 | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
836192 | ||
| CY2017 | us-gaap |
Dilutive Securities
DilutiveSecurities
|
||
| us-gaap |
Dilutive Securities
DilutiveSecurities
|
|||
| CY2017 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.02 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.58 | ||
| CY2017 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.02 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.58 | ||
| CY2017 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
||
| us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
|||
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.35 | |
| us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.35 | ||
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
1.142 | |
| us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.391 | ||
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
-1.463 | |
| us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
|||
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
|
-0.054 | |
| us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
|
|||
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.013 | |
| us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.001 | ||
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.038 | |
| us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.042 | ||
| CY2016Q2 | us-gaap |
Fair Value Inputs Discount Rate
FairValueInputsDiscountRate
|
0.29 | |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
1408658 | |
| CY2016Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
556592 | |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
8397000 | |
| CY2016Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
8397000 | |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
||
| CY2016Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
7840408 | |
| CY2016Q2 | us-gaap |
Fresh Start Adjustment Increase Decrease Additional Paid In Capital
FreshStartAdjustmentIncreaseDecreaseAdditionalPaidInCapital
|
17887966 | |
| CY2016Q2 | us-gaap |
Fresh Start Adjustment Increase Decrease Amortizable Intangible Assets
FreshStartAdjustmentIncreaseDecreaseAmortizableIntangibleAssets
|
8397000 | |
| CY2016Q2 | us-gaap |
Fresh Start Adjustment Increase Decrease Assets
FreshStartAdjustmentIncreaseDecreaseAssets
|
17528784 | |
| CY2016Q2 | us-gaap |
Fresh Start Adjustment Increase Decrease Cash And Cash Equivalents
FreshStartAdjustmentIncreaseDecreaseCashAndCashEquivalents
|
7052500 | |
| CY2016Q2 | us-gaap |
Fresh Start Adjustment Increase Decrease Common Stock
FreshStartAdjustmentIncreaseDecreaseCommonStock
|
750 | |
| CY2016Q2 | us-gaap |
Fresh Start Adjustment Increase Decrease Current Assets
FreshStartAdjustmentIncreaseDecreaseCurrentAssets
|
7052500 | |
| CY2016Q4 | us-gaap |
Fresh Start Adjustment Increase Decrease Goodwill
FreshStartAdjustmentIncreaseDecreaseGoodwill
|
2079284 | |
| CY2016Q2 | us-gaap |
Fresh Start Adjustment Increase Decrease Goodwill
FreshStartAdjustmentIncreaseDecreaseGoodwill
|
2079284 | |
| CY2016Q2 | us-gaap |
Fresh Start Adjustment Increase Decrease Liabilities And Stockholders Equity
FreshStartAdjustmentIncreaseDecreaseLiabilitiesAndStockholdersEquity
|
17528784 | |
| CY2016Q2 | us-gaap |
Fresh Start Adjustment Increase Decrease Preferred Stock
FreshStartAdjustmentIncreaseDecreasePreferredStock
|
3 | |
| CY2016Q2 | us-gaap |
Fresh Start Adjustment Increase Decrease Retained Earnings Deficit
FreshStartAdjustmentIncreaseDecreaseRetainedEarningsDeficit
|
-359935 | |
| CY2016Q2 | us-gaap |
Fresh Start Adjustment Increase Decrease Stockholders Equity
FreshStartAdjustmentIncreaseDecreaseStockholdersEquity
|
17528784 | |
| CY2017 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
1205 | |
| us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
|||
| CY2017 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3823929 | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3292348 | ||
| CY2016Q2 | us-gaap |
Goodwill
Goodwill
|
2100000 | |
| CY2017Q2 | us-gaap |
Goodwill
Goodwill
|
0 | |
| CY2017Q4 | us-gaap |
Goodwill
Goodwill
|
0 | |
| CY2015Q4 | us-gaap |
Goodwill
Goodwill
|
||
| CY2016Q4 | us-gaap |
Goodwill
Goodwill
|
2079284 | |
| CY2017 | us-gaap |
Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
|
9299223 | |
| us-gaap |
Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
|
|||
| us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
2100000 | ||
| CY2017 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
2079284 | |
| CY2017 | us-gaap |
Gross Profit
GrossProfit
|
-369997 | |
| us-gaap |
Gross Profit
GrossProfit
|
-256605 | ||
| CY2017 | us-gaap |
Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
6988342 | |
| CY2017Q4 | us-gaap |
Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
7000000 | |
| CY2016 | us-gaap |
Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
||
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-14978711 | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-5695627 | ||
| CY2017 | us-gaap |
Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
|
0 | |
| CY2016 | us-gaap |
Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
|
0 | |
| CY2017 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-119103 | |
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-48179 | ||
| CY2017 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
128067 | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-261103 | ||
| CY2017 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
-53503 | |
| CY2017 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
|||
| CY2017 | us-gaap |
Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
|
21900000 | |
| CY2017 | us-gaap |
Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
|
-277082 | |
| us-gaap |
Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
|
-584770 | ||
| CY2017 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-12335 | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-2484555 | ||
| CY2017 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-498120 | |
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-1839631 | ||
| CY2017 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
|||
| CY2017 | us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
||
| us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
|||
| CY2017 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-19358 | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
21573 | ||
| CY2017 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-152650 | |
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-77011 | ||
| us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
40 | ||
| CY2017 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
0 | |
| us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
|||
| CY2016Q2 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
8400000 | |
| CY2017Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
0 | |
| CY2016Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
7840408 | |
| CY2017 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
10800 | |
| us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
253000 | ||
| CY2017 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-10817 | |
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-2219 | ||
| CY2017 | us-gaap |
Interest Paid Net
InterestPaidNet
|
10765 | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
3629 | ||
| CY2017Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
40000 | |
| CY2016Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
18000 | |
| CY2017Q4 | us-gaap |
Inventory Net
InventoryNet
|
35590 | |
| CY2016Q4 | us-gaap |
Inventory Net
InventoryNet
|
69954 | |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
936837 | |
| CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1447292 | |
| CY2017Q4 | us-gaap |
Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
|
0 | |
| us-gaap |
License And Maintenance Revenue
LicenseAndMaintenanceRevenue
|
140000 | ||
| CY2015 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
3000000 | |
| CY2017 | us-gaap |
License Costs
LicenseCosts
|
||
| us-gaap |
License Costs
LicenseCosts
|
|||
| CY2017Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
18000 | |
| CY2016Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
60000 | |
| CY2017Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
23000 | |
| CY2016Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
8000 | |
| CY2017 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
15006 | |
| us-gaap |
Inventory Write Down
InventoryWriteDown
|
7967 | ||
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
941168 | |
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
1570726 | |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1424039 | |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
14056753 | |
| CY2017 | us-gaap |
Licenses Revenue
LicensesRevenue
|
||
| us-gaap |
Licenses Revenue
LicensesRevenue
|
|||
| CY2017 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> – Description of Business and Bankruptcy Proceedings</div></div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Description of Business</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Nuo Therapeutics, Inc. (“Nuo Therapeutics,” the “Company,” “we,” “us,” or “our”) is a biomedical company marketing its product primarily within the U.S. We commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The use of autologous (from self) biological therapies for tissue repair and regeneration is part of a transformative clinical strategy designed to improve long term recovery in complex chronic conditions with significant unmet medical needs. Growth opportunities for the Aurix System in the United States in the near to intermediate term include the treatment of chronic wounds with Aurix in: (i) the Medicare population under a National Coverage Determination (“NCD”), when registry data is collected under the Coverage with Evidence Development (“CED”) program of the Centers for Medicare & Medicaid Services (“CMS”); and (ii) the Veterans Affairs (“VA”) healthcare system and other federal accounts settings.</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">As of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017, </div>our commercial offering consists solely of the Aurix point of care technology for the safe and efficient separation of autologous blood to produce a platelet based therapy for the chronic wound care market. Prior to the Effective Date (as defined below), we had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> distinct platelet rich plasma (“PRP”) devices: the Aurix System for wound care, and the Angel® concentrated Platelet Rich Plasma (“cPRP”) System for orthopedics markets. Prior to the Effective Date, Arthrex, Inc. (“Arthrex”) was our exclusive distributor for Angel. Pursuant to the Plan of Reorganization (as defined below), on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> May 5, 2016, </div>the Company assigned its rights, title and interest in and to its existing license agreement with Arthrex to the Deerfield Lenders (as defined below), as well as rights to collect royalty payments thereunder.</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Bankruptcy Proceedings</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 26, 2016, </div>the Company filed a voluntary petition in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) seeking relief under Chapter <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> of Title <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> of the United States Code (the “Bankruptcy Code”), which is administered under the caption “In re: Nuo Therapeutics, Inc.”, Case <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10192</div> (MFW) (the “Chapter <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> Case”).</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> April 25, 2016 (</div>the “Confirmation Date”), the Bankruptcy Court entered an Order Granting Final Approval of Disclosure Statement and Confirming Debtor’s Plan of Reorganization (the “Confirmation Order”), which confirmed the Modified First Amended Plan of Reorganization of the Debtor under Chapter <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> of the Bankruptcy Code (as confirmed, the “Plan,” or “Plan of Reorganization”).</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Scenario A contemplated by the Plan of Reorganization became effective on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> May 5, 2016 (</div>the “Effective Date”). Pursuant to the Plan, as of the Effective Date: (i) all equity interests of the Company, including but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to all shares of the Company’s common stock, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.0001</div> par value per share (including its redeemable common stock) (the “Old Common Stock”), warrants, and options that were issuable or issued and outstanding immediately prior to the Effective Date, were cancelled; (ii) the Company’s certificate of incorporation that was in effect immediately prior to the Effective Date was amended and restated in its entirety; (iii) the Company’s by-laws that were in effect immediately prior to the Effective Date were amended and restated in their entirety; and (iv) the Company issued New Common Stock, Warrants and Series A Preferred Stock (all as defined below).</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Upon emergence from bankruptcy on the Effective Date, the Company applied fresh start accounting, resulting in the Company becoming a new entity for financial reporting purposes (see Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> – <div style="display: inline; font-style: italic;">Fresh Start Accounting</div>). As a result of the application of fresh start accounting, the Company reflected the disposition of its pre-petition debt and changes in its equity structure effected under the Confirmation Order in its balance sheet as of the Effective Date. Accordingly, all financial statements prior to <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> May 5, 2016 </div>are referred to as those of the "Predecessor Company", as they reflect the periods prior to application of fresh start accounting. The balance sheet as of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2016, </div>and the financial statements for periods subsequent to <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> May 4, 2016, </div>are referred to as those of the "Successor Company." Under fresh start accounting, the Company's assets and liabilities were adjusted to their fair values, and a reorganization value for the entity was determined by the Company based upon the estimated fair value of the enterprise before considering values allocated to debt to be settled in the reorganization. The fresh start adjustments are material and affect the Company’s results of operations from and after <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> May 5, 2016. </div>As a result of the application of fresh start accounting and the effects of the implementation of the Plan of Reorganization, the financial statements on or after <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> May 5, 2016 </div>are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> comparable to the financial statements prior to that date.</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Common Stock</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Recapitalization</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">In accordance with the Plan of Reorganization, as of the Effective Date, the Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,500,000</div> shares (the “Recapitalization Shares”) of new common stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.0001</div> per share (the “New Common Stock”), to certain accredited investors (the “Recapitalization Investors”) for gross cash proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,300,000</div> and net cash to the Company of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,052,500</div> (the “Recapitalization Financing”). <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">200,000</div> of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,500,000</div> shares of New Common Stock were issued in partial payment of an advisory fee. The net cash amount excludes the effect of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$100,000</div> in offering expenses paid from the proceeds of the DIP Financing (as defined below in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> - <div style="display: inline; font-style: italic;">Debt</div>), which was converted into Series A Preferred Stock as of the Effective Date, as described below under <div style="display: inline; font-style: italic;">“Series A Preferred Stock</div>.” As part of the Recapitalization Financing, the Company also issued warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,180,000</div> shares of New Common Stock to certain of the Recapitalization Investors (the “Warrants”). The Warrants terminate on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> May 5, 2021, </div>and are exercisable at any time on or after <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> November 5, 2016 </div>at exercise prices ranging from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.50</div> per share to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.75</div> per share. The number of shares of New Common Stock underlying a Warrant and its exercise price are subject to customary adjustments upon subdivisions, combinations, payment of stock dividends, reclassifications, reorganizations and consolidations. </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">A significant majority of the Recapitalization Investors executed backstop commitments to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,800,000</div> additional shares of New Common Stock for an aggregate purchase price of up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,000,000</div> (collectively, the “Backstop Commitment”). During the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017, </div>the Company exercised its rights under the Backstop Commitment in full and issued an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,800,000</div> shares of its common stock (the “Backstop Shares”) for gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million.</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">As of the Effective Date, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Recapitalization Investors. The Registration Rights Agreement provides certain resale registration rights to the Recapitalization Investors with respect to securities received in the Recapitalization Financing. Pursuant to the Registration Rights Agreement, the Company filed a registration statement, which was declared effective on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 11, 2017, </div>covering the resale of all shares of New Common Stock issued to the Recapitalization Investors on the Effective Date.</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Issuance of New Common Stock to Holders of Old Common Stock</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">As of the Effective Date, the Company committed to the issuance of up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,000,000</div> shares of New Common Stock and subsequently issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,264,612</div> shares of New Common Stock (the “Exchange Shares”) to record holders of the Old Common Stock as of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> March 28, 2016, </div>who executed and timely delivered the required release documents <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> later than <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> July 5, 2016, </div>in accordance with the Confirmation Order and the Plan. The holders of Old Common Stock who executed and timely delivered the required release documents are referred to as the “Releasing Holders.”</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,264,612</div> Exchange Shares were issued as of the Effective Date to Releasing Holders who asserted ownership of a number of shares of Old Common Stock that matched the Company’s records or could otherwise be confirmed at a rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of New Common Stock for every <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41.8934</div> shares of Old Common Stock held by such holders as of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> March 28, 2016. </div>In accordance with the Plan, if the calculation would otherwise have resulted in the issuance to any Releasing Holder of a number of shares of New Common Stock that is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> a whole number, then the number of shares actually issued to such Releasing Holder was determined by rounding down to the nearest number.</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Issuance of Shares in Exchange for Administrative Claims</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> June 20, 2016, </div>the Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">162,500</div> shares of New Common Stock (the “Administrative Claim Shares”) pursuant to the Order Granting Application of the Ad Hoc Equity Committee Pursuant to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> U.S.C. §§ <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">503</div>(b)(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>)(D) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">503</div>(b)(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>) for Allowance of Fees and Expenses Incurred in Making a Substantial Contribution, entered by the Bankruptcy Court on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> June 20, 2016. </div>The Administrative Claim Shares were issued to holders of administrative claims under sections <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">503</div>(b)(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>)(D) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">503</div>(b)(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>) of the Bankruptcy Code. Of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">162,500</div> shares, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000</div> shares were issued to outside counsel to the Ad Hoc Equity Committee of the Company’s equity holders as compensation of all remaining allowed fees for legal services provided by such counsel. The remaining <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">62,500</div> were issued to designees of the Ad Hoc Equity Committee who had granted loans in an aggregate amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$62,500</div> to the Ad Hoc Equity Committee in <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 2015 </div>as repayment of such loans.</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"> </div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Series A Preferred Stock</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On the Effective Date, the Company filed a Certificate of Designations of Series A Preferred Stock (the “Certificate of Designations”) with the Delaware Secretary of State, designating <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29,038</div> shares of the Company’s undesignated preferred stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.0001</div> per share, as Series A Preferred Stock (the “Series A Preferred Stock”). On the Effective Date, the Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29,038</div> shares of Series A Preferred Stock to Deerfield in accordance with the Plan pursuant to the exemption from the registration requirements of the Securities Act provided by Section <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1145</div> of the Bankruptcy Code. The Deerfield Lenders did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> receive any shares of New Common Stock or other equity interests in the Company.</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The Series A Preferred Stock has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> stated maturity date, is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> convertible or redeemable, and carries a liquidation preference of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$29,038,000,</div> which is required to be paid to holders of such Series A Preferred Stock before any payments are made with respect to shares of New Common Stock (and other capital stock that is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> issued on parity or senior to the Series A Preferred Stock) upon a liquidation or change in control transaction. For so long as Series A Preferred Stock is outstanding, the holders of Series A Preferred Stock have the right to nominate and elect <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> member of the board of directors of the Company (the “Board of Directors”) and to have such director serve on a standing committee of the Board of Directors established to exercise powers of the Board of Directors in respect of decisions or actions relating to the Backstop Commitment. The holders of the Series A Preferred Stock nominated and elected <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> member of the Board of Directors to serve as the designee of the holders of Series A Preferred Stock. The Series A Preferred Stock has voting rights, voting with the New Common Stock as a single class, with each share of Series A Preferred Stock having the right to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> votes, which currently represents approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> percent (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1%</div>) of the voting rights of the capital stock of the Company. The holders of Series A Preferred Stock have the right to approve certain transactions and incurrences of debt. The Certificate of Designations limits the Company’s ability to pay dividends on or purchase shares of its capital stock.</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Assignment and Assumption Agreement; Transition Services Agreement</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Pursuant to the Plan, on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> May 5, 2016, </div>the Company entered into an Assignment and Assumption Agreement with Deerfield SS, LLC (the “Assignee”), the designee of the Deerfield Lenders, to assign to the Assignee the Company’s rights, title and interest in and to its existing license agreement with Arthrex, and to transfer and assign to the Assignee associated intellectual property owned by the Company and licensed thereunder, as well as rights to collect royalty payments thereunder. The assignment and transfer was effected in exchange for a reduction of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15,000,000</div> in the amount of the allowed claim of the Deerfield Lenders pursuant to the Plan. As a result of the assignment and transfer, the Aurix System currently represents the Company’s only commercial product offering.</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On the Effective Date, the Company and the Assignee entered into a Transition Services Agreement in which the Company agreed to continue to service its license agreement with Arthrex for a transition period.</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Termination of Deerfield Facility Agreement and DIP Credit Agreement</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On the Effective Date, the obligations of the Company under the Deerfield Facility Agreement, and under the DIP Credit Agreement (as defined below in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div> - <div style="display: inline; font-style: italic;">Debt</div>), were cancelled in accordance with the Plan of Reorganization, and the Company ceased to have any obligations thereunder.</div></div> | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
2922029 | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
|||
| CY2017 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
55417 | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
99960 | ||
| CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4903954 | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-7838146 | ||
| CY2017 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-14978711 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-5695627 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-5695627 | ||
| CY2017 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-14978711 | |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-5695027 | ||
| CY2017 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-14978711 | |
| us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-5695027 | ||
| CY2017 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
555497 | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-237665 | ||
| CY2017 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2017 | us-gaap |
Number Of Reporting Units
NumberOfReportingUnits
|
1 | |
| CY2017 | us-gaap |
Operating Expenses
OperatingExpenses
|
15164211 | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
5201357 | ||
| CY2017 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-15534208 | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5457962 | ||
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
563000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
441000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
122000 | |
| CY2017 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
270000 | |
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
87000 | ||
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
180000 | ||
| CY2017Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
155000000 | |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
241485 | |
| CY2016Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
124484 | |
| CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
15316 | |
| CY2016Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
278730 | |
| us-gaap |
Other Income
OtherIncome
|
50000 | ||
| CY2017Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
4331 | |
| CY2016Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
123434 | |
| CY2017 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
566314 | |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
89105 | ||
| CY2017 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
471 | |
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
|||
| CY2016Q2 | us-gaap |
Postconfirmation Additional Paid In Capital
PostconfirmationAdditionalPaidInCapital
|
17887966 | |
| CY2016Q2 | us-gaap |
Postconfirmation Amortizable Intangible Assets
PostconfirmationAmortizableIntangibleAssets
|
8397000 | |
| CY2016Q2 | us-gaap |
Postconfirmation Amortizable Intangible Assets
PostconfirmationAmortizableIntangibleAssets
|
8397000 | |
| CY2016Q2 | us-gaap |
Postconfirmation Assets
PostconfirmationAssets
|
24049746 | |
| CY2016Q2 | us-gaap |
Postconfirmation Cash And Cash Equivalents
PostconfirmationCashAndCashEquivalents
|
10358209 | |
| CY2016Q2 | us-gaap |
Postconfirmation Common Stock
PostconfirmationCommonStock
|
750 | |
| CY2016Q2 | us-gaap |
Postconfirmation Current Assets
PostconfirmationCurrentAssets
|
12352005 | |
| CY2016Q2 | us-gaap |
Postconfirmation Goodwill
PostconfirmationGoodwill
|
2079000 | |
| CY2016Q2 | us-gaap |
Postconfirmation Goodwill
PostconfirmationGoodwill
|
2079284 | |
| CY2016Q2 | us-gaap |
Postconfirmation Inventories
PostconfirmationInventories
|
56348 | |
| CY2016Q2 | us-gaap |
Postconfirmation Liabilities
PostconfirmationLiabilities
|
6161027 | |
| CY2016Q2 | us-gaap |
Postconfirmation Liabilities And Stockholders Equity
PostconfirmationLiabilitiesAndStockholdersEquity
|
24049746 | |
| CY2016Q2 | us-gaap |
Postconfirmation Liabilities Subject To Compromise
PostconfirmationLiabilitiesSubjectToCompromise
|
||
| CY2016Q2 | us-gaap |
Postconfirmation Preferred Stock
PostconfirmationPreferredStock
|
3 | |
| CY2016Q2 | us-gaap |
Postconfirmation Prepaid And Other Current Assets
PostconfirmationPrepaidAndOtherCurrentAssets
|
595540 | |
| CY2016Q2 | us-gaap |
Postconfirmation Property And Equipment Net
PostconfirmationPropertyAndEquipmentNet
|
865716 | |
| CY2016Q2 | us-gaap |
Postconfirmation Receivables Net
PostconfirmationReceivablesNet
|
1288445 | |
| CY2016Q2 | us-gaap |
Postconfirmation Restricted Cash And Cash Equivalents Current
PostconfirmationRestrictedCashAndCashEquivalentsCurrent
|
53463 | |
| CY2016Q2 | us-gaap |
Postconfirmation Retained Earnings Deficit
PostconfirmationRetainedEarningsDeficit
|
||
| CY2016Q2 | us-gaap |
Postconfirmation Stockholders Equity
PostconfirmationStockholdersEquity
|
17888719 | |
| CY2016Q2 | us-gaap |
Preconfirmation Additional Paid In Capital
PreconfirmationAdditionalPaidInCapital
|
126011808 | |
| CY2016Q2 | us-gaap |
Preconfirmation Amortizable Intangible Assets Net
PreconfirmationAmortizableIntangibleAssetsNet
|
2406457 | |
| CY2016Q2 | us-gaap |
Preconfirmation Assets
PreconfirmationAssets
|
8943472 | |
| CY2016Q2 | us-gaap |
Preconfirmation Cash And Cash Equivalents
PreconfirmationCashAndCashEquivalents
|
3305709 | |
| CY2016Q2 | us-gaap |
Preconfirmation Common Stock
PreconfirmationCommonStock
|
12477 | |
| CY2016Q2 | us-gaap |
Preconfirmation Current Assets
PreconfirmationCurrentAssets
|
5315558 | |
| CY2016Q2 | us-gaap |
Preconfirmation Goodwill
PreconfirmationGoodwill
|
0 | |
| CY2016Q2 | us-gaap |
Preconfirmation Inventories
PreconfirmationInventories
|
56348 | |
| CY2016Q2 | us-gaap |
Preconfirmation Liabilities
PreconfirmationLiabilities
|
51900824 | |
| CY2016Q2 | us-gaap |
Preconfirmation Liabilities And Stockholders Equity
PreconfirmationLiabilitiesAndStockholdersEquity
|
8943472 | |
| CY2016Q2 | us-gaap |
Preconfirmation Liabilities Subject To Compromise
PreconfirmationLiabilitiesSubjectToCompromise
|
39089877 | |
| CY2016Q2 | us-gaap |
Preconfirmation Preferred Stock
PreconfirmationPreferredStock
|
0 | |
| CY2016Q2 | us-gaap |
Preconfirmation Prepaid And Other Current Assets
PreconfirmationPrepaidAndOtherCurrentAssets
|
611593 | |
| CY2016Q2 | us-gaap |
Preconfirmation Property And Equipment Net
PreconfirmationPropertyAndEquipmentNet
|
865716 | |
| CY2016Q2 | us-gaap |
Preconfirmation Receivables Net
PreconfirmationReceivablesNet
|
1288445 | |
| CY2016Q2 | us-gaap |
Preconfirmation Restricted Cash And Cash Equivalents Current
PreconfirmationRestrictedCashAndCashEquivalentsCurrent
|
53463 | |
| CY2016Q2 | us-gaap |
Preconfirmation Retained Earnings Deficit
PreconfirmationRetainedEarningsDeficit
|
-169874587 | |
| CY2016Q2 | us-gaap |
Preconfirmation Stockholders Equity
PreconfirmationStockholdersEquity
|
-43457352 | |
| CY2017Q4 | us-gaap |
Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
|
29038000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
|
29038000 | |
| CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2016Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
29038 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
29038 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
29038 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
29038 | |
| CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
3 | |
| CY2016Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
3 | |
| CY2017Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
341671 | |
| CY2016Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
334437 | |
| CY2017 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3000000 | |
| CY2017Q3 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3000000 | |
| CY2017Q3 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3000000 | |
| CY2017 | us-gaap |
Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
|
||
| us-gaap |
Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
|
|||
| CY2017 | us-gaap |
Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
|
1914 | |
| us-gaap |
Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
|
100000 | ||
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
762340 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
765717 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
223616 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
486116 | |
| CY2017 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
-97115 | |
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
409377 | ||
| CY2017 | us-gaap |
Reorganization Items
ReorganizationItems
|
||
| us-gaap |
Reorganization Items
ReorganizationItems
|
324551 | ||
| CY2016Q2 | us-gaap |
Reorganization Value
ReorganizationValue
|
24050000 | |
| CY2016Q2 | us-gaap |
Reorganization Value
ReorganizationValue
|
24050000 | |
| CY2017Q4 | us-gaap |
Reorganization Value Present Value Of Discounted Cash Flows Of Emerging Entity
ReorganizationValuePresentValueOfDiscountedCashFlowsOfEmergingEntity
|
||
| CY2016Q4 | us-gaap |
Reorganization Value Present Value Of Discounted Cash Flows Of Emerging Entity
ReorganizationValuePresentValueOfDiscountedCashFlowsOfEmergingEntity
|
1507863 | |
| CY2016Q4 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
201200 | |
| CY2017 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1328324 | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1015871 | ||
| CY2017Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
||
| CY2016Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
53503 | |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-20674808 | |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-5695627 | |
| CY2017 | us-gaap |
Revenues
Revenues
|
721045 | |
| us-gaap |
Revenues
Revenues
|
472445 | ||
| CY2017 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
190110 | |
| us-gaap |
Royalty Revenue
RoyaltyRevenue
|
106050 | ||
| CY2017 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
530935 | |
| us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
366395 | ||
| CY2017 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
712735 | |
| us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
893138 | ||
| CY2017 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
53526 | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
74999 | ||
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
||
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
||
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.83 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.83 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
1265000 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
1 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P9Y186D | ||
| CY2017 | us-gaap |
Stock Issued1
StockIssued1
|
||
| us-gaap |
Stock Issued1
StockIssued1
|
217936 | ||
| CY2017 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
12800000 | |
| CY2017Q3 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
12800000 | |
| CY2017Q3 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
12800000 | |
| us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
217936 | ||
| CY2016Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
9600000 | |
| us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
|||
| CY2017 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
2922500 | |
| CY2017 | us-gaap |
Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
|
471 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
482871 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
12486027 | |
| CY2016Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
17888719 | |
| CY2017Q4 | us-gaap |
Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
|
3484175 | |
| CY2016Q4 | us-gaap |
Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
|
3484799 | |
| CY2017 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Use of Estimates</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to, the application of fresh start accounting, stock-based compensation, allowance for inventory obsolescence, allowance for doubtful accounts, contingent liabilities, fair value, recoverability and depreciable lives of long-lived assets (including property and equipment, intangible assets and goodwill), deferred taxes and associated valuation allowance and the classification of our long-term debt. Actual results could differ from those estimates.</div></div></div> | |
| CY2017 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
-13587549 | |
| CY2017 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
14646112 | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
9895966 | ||
| CY2017 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
14646112 | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
9895966 |
